This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Martin M, Moore L, Quilici S, File TM, GARAU J, Kubin M, Evers T.Cost-effectiveness of moxifloxacin for the treatment of community-acquired pneumonia in countries with differing levels of antimicrobial resistance. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 467 (plus poster) abstr. O-1863, 17 Sep 2007
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL.Cost effectivenes of telavancin vs. vancomycin for the treatment of complicated skin and skin structure infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 469 (plus poster) abstr. O-1871, 17 Sep 2007
Earnshaw SR, Graham CN, Gasper SM.Cost effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 468, 17 Sep 2007
McIntosh EDG, Wu D, Paradiso P, Tucker H, Burlington B, Papiernick D, Barrett L, Woodrow A, Mallick R.Pandemic flu preparedness and antibiotics: projected health care utilisation and recommendation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 470, 17 Sep 2007
Rights and permissions
About this article
Cite this article
News from ICAAC. Pharmacoecon. Outcomes News 538, 7–8 (2007). https://doi.org/10.2165/00151234-200705380-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705380-00015